BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3561699)

  • 1. Neurological abnormalities in Wilson's disease are reversible.
    Lingam S; Wilson J; Nazer H; Mowat AP
    Neuropediatrics; 1987 Feb; 18(1):11-2. PubMed ID: 3561699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Wilson's disease with triethylene tetramine dihydrochloride. A case report.
    Haslam RH; Sass-Kortsak A; Stout W; Berg M
    Dev Pharmacol Ther; 1980; 1(5):318-24. PubMed ID: 7438976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Triethylene tetramine in Wilson's disease].
    Rave D; Vengrover D; Kleinman J; Leitersdorf E
    Harefuah; 1986 Feb; 110(4):178-9. PubMed ID: 3721331
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine).
    Dahlman T; Hartvig P; Löfholm M; Nordlinder H; Lööf L; Westermark K
    QJM; 1995 Sep; 88(9):609-16. PubMed ID: 7583074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The management of Wilson's disease with trienthylene tetramine 2HC1 (Trien 2HC1).
    Walshe JM
    Prog Clin Biol Res; 1979; 34():271-80. PubMed ID: 531055
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease.
    Scheinberg IH; Jaffe ME; Sternlieb I
    N Engl J Med; 1987 Jul; 317(4):209-13. PubMed ID: 3600712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Wilson's disease.
    Brewer GJ; Yuzbasiyan-Gurkan V; Young AB
    Semin Neurol; 1987 Jun; 7(2):209-20. PubMed ID: 3332455
    [No Abstract]   [Full Text] [Related]  

  • 8. Trientine for Wilson's disease.
    Med Lett Drugs Ther; 1986 Jul; 28(717):67. PubMed ID: 3724656
    [No Abstract]   [Full Text] [Related]  

  • 9. [Trientin in Wilson's disease. Therapeutic possibilities in patients who cannot tolerate penicillamine].
    Ritland S
    Tidsskr Nor Laegeforen; 1987 Aug; 107(22):1770-1. PubMed ID: 3660361
    [No Abstract]   [Full Text] [Related]  

  • 10. [Control of the therapeutic prevention of copper uptake in the liver in Wilson's disease following oral administration of 64Cu].
    Günther K; Siegemund R; Lössner J; Kühn HJ
    Radiobiol Radiother (Berl); 1988; 29(2):226-9. PubMed ID: 3399664
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of Wilson's disease using triethylenetetramine dihydrochloride (TETA)].
    Hauftová D; Körbel J; Jancík F; Kuhr I; Ferenc M
    Cesk Gastroenterol Vyz; 1978 Dec; 32(8):538-9. PubMed ID: 737791
    [No Abstract]   [Full Text] [Related]  

  • 12. The management of pregnancy in Wilson's disease treated with trientine.
    Walshe JM
    Q J Med; 1986 Jan; 58(225):81-7. PubMed ID: 3704107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathogenesis and treatment of Wilson's disease].
    Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
    Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wilson's disease. An analysis of the cranial computerized tomographic appearances found in 60 patients and the changes in response to treatment with chelating agents.
    Williams FJ; Walshe JM
    Brain; 1981 Dec; 104(Pt 4):735-52. PubMed ID: 7326565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chelation treatment of neurological Wilson's disease.
    Walshe JM; Yealland M
    Q J Med; 1993 Mar; 86(3):197-204. PubMed ID: 8369040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurological Wilson's disease.
    McIntyre N
    Q J Med; 1993 May; 86(5):349-50. PubMed ID: 8327653
    [No Abstract]   [Full Text] [Related]  

  • 17. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease.
    Siafakas CG; Jonas MM; Alexander S; Herrin J; Furuta GT
    Am J Gastroenterol; 1998 Dec; 93(12):2544-6. PubMed ID: 9860423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver transplantation: treatment of choice for hepatic and neurological manifestation of Wilson's disease.
    Schumacher G; Platz KP; Mueller AR; Neuhaus R; Steinmüller T; Bechstein WO; Becker M; Luck W; Schuelke M; Neuhaus P
    Clin Transplant; 1997 Jun; 11(3):217-24. PubMed ID: 9193846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilson's disease presenting with features of hepatic dysfunction: a clinical analysis of eighty-seven patients.
    Walshe JM
    Q J Med; 1989 Mar; 70(263):253-63. PubMed ID: 2602537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug therapy in Wilson's disease.
    Reed K
    J Am Optom Assoc; 1988 Jun; 59(6):438. PubMed ID: 3403885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.